b16 f1 mouse melanoma cells  (ATCC)

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: B16F1 cellular behaviors of A@DFX, AB@DFX and RGD AB@DFX NPs (A) Fluorescence microscopy images of cells treated with various FITC-labeled NPs for 6 h. Scale bars, 10 μm. ( n = 3 independent biological replicates). (B) Cell viability assessment after 24 h of incubation with cells by MTT assay. Data are expressed as means ± SD ( n = 3 independent biological replicates). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (C) Western blot analysis of p -AKT and PD-L1 expression of cells treated with various NPs for 6 h ( n = 3 independent biological replicates).

Article Snippet: Murine melanoma B16F1 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Fluorescence, Microscopy, Labeling, Incubation, MTT Assay, Western Blot, Expressing

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: Pharmacokinetics and biodistribution of various NPs in B16F1 tumor-bearing mice (A) Plasma concentration-time curve of DFX of mice intravenously injected with DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs during 24 h. Data are expressed as means ± SD ( n = 3 mice). (B) Ex vivo fluorescence images of tumor and major organs (heart, liver, spleen, lung, and kidney) of mice intravenously injected with DiR-labeled NPs ( RGD AB@DiR NPs, AB@DiR NPs and A@DiR NPs) and DiR; the fluorescence images were collected at 24 h post-injection ( n = 3 mice). (C) Quantitative fluorescence intensity analysis in (B). Data are expressed as means ± SD ( n = 3 mice).

Article Snippet: Murine melanoma B16F1 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Drug discovery, Clinical Proteomics, Concentration Assay, Injection, Ex Vivo, Fluorescence, Labeling

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: In vivo therapeutic effect of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) Tumor growth curves during 21 days of treatment with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Data are expressed as means ± SD ( n = 3 mice). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (B) Photographs of tumors at the end of 21 days of various treatments ( n = 3 mice). (C) PD-L1 expression of tumor tissues at the end of 21 days of various treatments ( n = 3 independent biological replicates). (D) H&E staining of tumor tissue sections at the end of 21 days of various treatments. Scale bars, 100 μm.

Article Snippet: Murine melanoma B16F1 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: In Vivo, Expressing, Staining

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: Biocompatibility of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) H&E staining of major organs (heart, liver, spleen, lung and kidney) at the end of 21 days of treatments with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Scale bars, 100 μm. (B) Blood routine indices of mice at the end of 21 days of various treatments. Data are expressed as means ± SD ( n = 3 mice).

Article Snippet: Murine melanoma B16F1 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Staining

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: B16F1 cellular behaviors of A@DFX, AB@DFX and RGD AB@DFX NPs (A) Fluorescence microscopy images of cells treated with various FITC-labeled NPs for 6 h. Scale bars, 10 μm. ( n = 3 independent biological replicates). (B) Cell viability assessment after 24 h of incubation with cells by MTT assay. Data are expressed as means ± SD ( n = 3 independent biological replicates). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (C) Western blot analysis of p -AKT and PD-L1 expression of cells treated with various NPs for 6 h ( n = 3 independent biological replicates).

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: Fluorescence, Microscopy, Labeling, Incubation, MTT Assay, Western Blot, Expressing

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: Pharmacokinetics and biodistribution of various NPs in B16F1 tumor-bearing mice (A) Plasma concentration-time curve of DFX of mice intravenously injected with DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs during 24 h. Data are expressed as means ± SD ( n = 3 mice). (B) Ex vivo fluorescence images of tumor and major organs (heart, liver, spleen, lung, and kidney) of mice intravenously injected with DiR-labeled NPs ( RGD AB@DiR NPs, AB@DiR NPs and A@DiR NPs) and DiR; the fluorescence images were collected at 24 h post-injection ( n = 3 mice). (C) Quantitative fluorescence intensity analysis in (B). Data are expressed as means ± SD ( n = 3 mice).

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: Drug discovery, Clinical Proteomics, Concentration Assay, Injection, Ex Vivo, Fluorescence, Labeling

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: In vivo therapeutic effect of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) Tumor growth curves during 21 days of treatment with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Data are expressed as means ± SD ( n = 3 mice). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (B) Photographs of tumors at the end of 21 days of various treatments ( n = 3 mice). (C) PD-L1 expression of tumor tissues at the end of 21 days of various treatments ( n = 3 independent biological replicates). (D) H&E staining of tumor tissue sections at the end of 21 days of various treatments. Scale bars, 100 μm.

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: In Vivo, Expressing, Staining

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: Biocompatibility of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) H&E staining of major organs (heart, liver, spleen, lung and kidney) at the end of 21 days of treatments with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Scale bars, 100 μm. (B) Blood routine indices of mice at the end of 21 days of various treatments. Data are expressed as means ± SD ( n = 3 mice).

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: Staining